InvestorsHub Logo
Followers 839
Posts 120480
Boards Moderated 18
Alias Born 09/05/2002

Re: DewDiligence post# 912

Monday, 10/19/2020 10:03:16 AM

Monday, October 19, 2020 10:03:16 AM

Post# of 1169
Opdivo/Cabometyx BLA/NDA for RCC combination therapy has 2/21/21 PDUFA (with FDA priority review):

https://www.businesswire.com/news/home/20201019005198/en

Since the treatment regimen, from the CHECKMATE-9ER study, is a combination of a biologic (Opdivo) and a small-molecule TKI (Cabometyx), the FDA is conducting separate but simultaneous reviews for each component, something you don’t often see.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BMY News